# EndoDetectAI - GI Polyp Detection Platform
## Venture Specification

**Date:** 2026-03-02
**Category:** Healthcare AI / Medical Devices
**Status:** GO - 8.00/10
**Target:** Gastroenterologists and GI Centers

---

## Executive Summary

EndoDetectAI is an AI-powered platform for gastroenterologists that automates real-time colonoscopy polyp detection, upper GI lesion detection, adenoma detection rate (ADR) tracking, and endoscopy quality metrics. The platform addresses the critical problem of missed polyps during colonoscopy, which directly correlates with colorectal cancer risk and physician liability.

**Go/No-Go Decision:** GO

**Key Insight:** Adenoma Detection Rate (ADR) is now a quality metric tied to Medicare reimbursement. Physicians with low ADRs face financial penalties and credentialing consequences. AI-assisted detection improves ADR by 10-30%, creating immediate ROI.

---

## 1. Core Concept

AI-powered computer vision platform that provides real-time detection and classification of polyps and lesions during endoscopic procedures. The system integrates with existing endoscopy equipment to:

1. **Real-time polyp detection** during colonoscopy
2. **Adenoma vs. hyperplastic classification** for clinical decision-making
3. **Upper GI lesion detection** (esophageal, gastric, duodenal)
4. **ADR tracking and analytics** for quality improvement
5. **Procedure quality metrics** (withdrawal time, cecal intubation rate)
6. **Lesion size estimation** for resection planning

---

## 2. Problem Statement

### Clinical Problem

- **Missed polyps are deadly:** 6-12% of colorectal cancers occur within 3 years of colonoscopy (interval cancers)
- **Missed polyps = liability:** Malpractice claims for missed cancers average $2.3M
- **ADR variation:** Physician ADR ranges from 7% to 53% (national average: 25%)
- **Upper GI lesions:** Esophageal and gastric cancers often missed during routine EGD

### Economic Problem

- **ADR reimbursement tie:** Medicare now links ADR to quality metrics and reimbursement
- **Credentialing risk:** Low ADR physicians face hospital privileges revocation
- **12,000+ gastroenterologists** in US with varying quality outcomes
- **19M+ colonoscopies** annually in US (growing 4% YoY)

### Pain Points by Role

| Role | Primary Pain |
|------|-------------|
| Individual Endoscopist | Malpractice fear, ADR pressure, credentialing risk |
| GI Center Director | Quality metrics, patient outcomes, liability exposure |
| Ambulatory Surgery Center | Accreditation requirements, reimbursement optimization |
| Hospital Admin | Quality reporting, patient safety, liability management |

---

## 3. Target Market

### Primary Market: Gastroenterologists

**Total Addressable Market (TAM):**
- 12,000+ gastroenterologists in US
- 4,000+ ambulatory surgery centers with endoscopy suites
- $3.6B annual addressable market

**Serviceable Addressable Market (SAM):**
- 3,000 high-volume endoscopists (250+ procedures/year)
- 1,500 GI centers with quality improvement programs
- $900M SAM

**Serviceable Obtainable Market (SOM):**
- 150 suites in Year 1 (5% of SAM)
- $1.6M ARR

### Secondary Markets

1. **Hospital Endoscopy Suites** (2,000+ facilities)
2. **GI Device Manufacturers** (Olympus, Fujifilm, Pentax - OEM partnerships)
3. **International Markets** (EU, Japan - regulatory clearance required)

### Ideal Customer Profile

**Must-Have Criteria:**
- High-volume endoscopist (200+ colonoscopies/year)
- Quality-conscious (tracks ADR, participates in QI programs)
- Malpractice-conscious (prior claims or near-misses)
- Tech-adopting (uses modern EHR, practice management)

**Nice-to-Have Criteria:**
- Academic affiliation (research interest)
- Multi-physician practice (economies of scale)
- Ambulatory surgery center owner (control over equipment)

---

## 4. Why Now

### Market Timing Drivers

1. **ADR Reimbursement Tie** (2023+)
   - Medicare Merit-based Incentive Payment System (MIPS)
   - ADR now publicly reported (Physician Compare website)
   - Financial penalties for low ADR physicians

2. **Colonoscopy Demand Surge**
   - Colorectal cancer screening age lowered to 45 (2021)
   - 10M+ new eligible patients in US
   - 4% annual procedure growth

3. **AI Technology Proven**
   - GI Genius (Medtronic) FDA approved (2021)
   - Multiple peer-reviewed studies show 10-30% ADR improvement
   - Real-time CNN processing now feasible on edge hardware

4. **Liability Crisis**
   - Malpractice premiums rising 8% YoY
   - Interval cancer lawsuits highly publicized
   - Hospitals credentialing based on ADR

5. **Hardware Ecosystem Ready**
   - Endoscopy manufacturers adopting AI-ready platforms
   - Edge computing hardware sufficient for real-time processing
   - Video capture standards established (DICOM, MPEG)

### Regulatory Tailwinds

- **FDA De Novo pathway** established for AI diagnostic aids
- **CMS reimbursement codes** for AI-assisted procedures emerging
- **Quality metric programs** (MIPS, APMs) incentivizing adoption

---

## 5. AI Advantage

### Technical Capabilities

| Feature | AI Approach | Clinical Impact |
|---------|-------------|-----------------|
| Real-time polyp detection | CNN on endoscopic video stream | 10-30% ADR improvement |
| Adenoma classification | ResNet fine-tuned on pathology-confirmed images | Reduce unnecessary resection |
| Lesion size estimation | Computer vision + depth estimation | Resection planning |
| Upper GI lesion detection | Multi-class CNN (Barrett's, gastric cancer, etc.) | Earlier cancer detection |
| Quality metrics | Computer vision + sensor fusion | Withdrawal time compliance |

### Clinical Validation

**Published Performance Targets:**
- Sensitivity: >90% for polyps >5mm (cannot miss)
- Specificity: >80% (minimize false positives)
- ADR Improvement: 10-30% absolute increase
- Latency: <200ms (real-time requirement)

### Data Moat

**Proprietary Data Assets:**
- Annotated endoscopic video dataset (scarce resource)
- Pathology-confirmed polyp images (gold standard)
- Procedure outcome data (long-term validation)
- International lesion variations (training diversity)

---

## 6. Viral Mechanism

### Referral Drivers

1. **"Career-Saving" Case Studies**
   - "AI caught 12mm adenoma I missed"
   - Stories spread at DDW, ACG, ASGE conferences
   - Fear of missing polyps = powerful motivator

2. **Malpractice Defense**
   - "AI-assisted procedure" = liability mitigation
   - Attorneys recommend AI adoption
   - Insurance premium discounts

3. **Quality Metric Competition**
   - Public ADR rankings on Physician Compare
   - Physicians want to be top performers
   - AI provides competitive advantage

### Conference Strategy

**Primary Conferences:**
- DDW (Digestive Disease Week) - 15,000+ attendees
- ACG (American College of Gastroenterology) Annual Meeting
- ASGE (American Society for Gastrointestinal Endoscopy) Annual Meeting

**Tactics:**
- Live demonstration of real-time detection
- "AI vs. Human" detection competition
- Peer-reviewed research presentations
- Case study videos from early adopters

### Thought Leadership

- Publish ADR improvement studies
- Host quality improvement webinars
- Partner with GI society guidelines committees
- Create ADR benchmarking reports

---

## 7. Revenue Model

### Pricing Tiers

| Tier | Price | Features | Target |
|------|-------|----------|--------|
| Starter | $2,000/month | Colonoscopy polyp detection, ADR tracking | Individual endoscopists |
| Professional | $3,000/month | Full suite + upper GI + quality metrics | GI centers, practices |
| Enterprise | $6,000/month | Multi-center + white-label + research | Hospital systems, ASCs |

### Per-Procedure Add-On

- $25 per AI-assisted colonoscopy (beyond included tiers)
- Billed monthly based on usage
- Discounts for volume commitments

### Implementation Fees

- Hardware setup: $5,000 one-time
- Integration fee: $10,000 (EHR, endoscopy systems)
- Training: $2,000 (on-site staff training)

### Unit Economics

| Metric | Value | Notes |
|--------|-------|-------|
| ARPU | $36,000/year | Professional tier average |
| CAC | $300 | Conference booth + demos |
| LTV | $108,000 | 36-month retention (switching costs) |
| Gross Margin | 85% | Software + support |
| CAC Payback | 1 month | Instant ROI from ADR improvement |

### Upsell Path

1. **Start:** Colonoscopy detection (Starter tier)
2. **Upgrade:** Upper GI + quality metrics (Professional tier)
3. **Expand:** Multi-site deployment (Enterprise tier)
4. **Add:** Per-procedure billing for high-volume users

---

## 8. MVP Roadmap (8 Weeks)

### Weeks 1-2: Data Collection & Partnership

**Goals:**
- Secure one GI center partnership
- Collect 100+ annotated polyp videos
- Establish data pipeline infrastructure

**Deliverables:**
- Data sharing agreement with GI center
- Video annotation platform
- Initial training dataset (50+ hours)

### Weeks 3-5: Model Development

**Goals:**
- Build polyp detection CNN for real-time video
- Achieve >0.90 sensitivity for polyps >5mm
- Optimize for <200ms latency

**Deliverables:**
- Trained detection model
- Real-time inference pipeline
- Integration with endoscopy video output

### Weeks 6-7: Pilot Deployment

**Goals:**
- Deploy at partner GI center
- Validate detection vs. endoscopist
- Measure ADR improvement

**Deliverables:**
- In-clinic deployment
- Validation study (50+ procedures)
- Clinical performance metrics

### Week 8: Refinement & Demo Prep

**Goals:**
- Refine model based on pilot feedback
- Prepare DDW conference demo
- Document clinical validation

**Deliverables:**
- Refined model v0.2
- Conference demo materials
- Clinical case study document

### MVP Validation Metrics

| Metric | Target | Why It Matters |
|--------|--------|----------------|
| Sensitivity | >90% for polyps >5mm | Cannot miss clinically significant polyps |
| Specificity | >80% | Avoid alert fatigue |
| ADR Improvement | 10%+ absolute increase | Quality metric improvement |
| Latency | <200ms | Real-time requirement |
| Pilot Conversion | 1 GI center commits | Product-market fit signal |

---

## 9. Technology Stack

### AI/ML Layer

```yaml
Model Architecture:
  - Backbone: ResNet50 / EfficientNet (pre-trained ImageNet)
  - Detection: YOLOv8 / RetinaNet (real-time object detection)
  - Classification: Fine-tuned on polyp histology dataset
  - Segmentation: U-Net (lesion boundary detection)

Training Infrastructure:
  - Framework: PyTorch 2.x
  - Hardware: NVIDIA A100 GPUs (AWS p4 instances)
  - Data Augmentation: Albumentations (video-specific)
  - Experiment Tracking: Weights & Biases
```

### Real-Time Inference

```yaml
Edge Deployment:
  - Hardware: NVIDIA Jetson Orin / Xavier
  - Framework: TensorRT (optimized inference)
  - Latency Target: <200ms end-to-end
  - Video Processing: OpenCV + GStreamer
```

### Backend Services

```yaml
API Layer:
  - Framework: FastAPI (Python)
  - Authentication: OAuth 2.0 + SAML (hospital SSO)
  - Rate Limiting: Per-suite quotas

Data Layer:
  - Database: PostgreSQL (procedural data)
  - Object Storage: S3 (video archives)
  - Cache: Redis (session management)
  - Search: Elasticsearch (case study library)
```

### Integrations

```yaml
Endoscopy Systems:
  - Olympus: EVIS LUCERA / EXERA series
  - Fujifilm: ELUXEO / 700 series
  - Pentax: EPK-i series
  - Capture: SDI / HDMI / USB video output

EHR Integration:
  - Epic: FHIR APIs
  - Cerner: HealthConnect
  - Meditech: Magic/API
  - Procedure Documentation: Automatic coding

Quality Reporting:
  - GIQuIC: ADR registry
  - MIPS: Quality metric submission
  - Physician Compare: Public reporting
```

### Infrastructure

```yaml
Cloud:
  - Provider: AWS (US-East, US-West)
  - Compliance: HIPAA BAA, SOC 2 Type II
  - Regions: US-only (clinical data)

Edge Deployment:
  - Hardware: NVIDIA Jetson Orin
  - Containerization: Docker + NVIDIA runtime
  - Updates: OTA with rollback capability

Security:
  - Encryption: AES-256 at rest, TLS 1.3 in transit
  - Access: RBAC + audit logging
  - PHI: De-identified for ML training
```

---

## 10. Market Analysis

### Competitive Landscape

| Competitor | Product | Pros | Cons | Our Differentiation |
|------------|---------|------|------|---------------------|
| Medtronic | GI Genius | FDA approved, strong distribution | $10K/year, Olympus-only | Vendor-agnostic, ADR tracking |
| Fujifilm | CAD EYE | Integrated with scopes | Fujifilm scopes only | Cross-vendor, upper GI |
| Olympus | EndoAid | Built into new systems | New systems only | Retrofit any endoscopy room |
| Iterative Scans | SKOUT | FDA approved | Colonoscopy only | Full GI suite + ADR analytics |
| Several startups | Various | Low cost | Unproven, no FDA | Clinical validation focus |

### Differentiation Strategy

1. **Vendor-Agnostic Platform**
   - Works with any endoscopy system (Olympus, Fujifilm, Pentax)
   - No capital equipment requirement
   - Lower barrier to adoption

2. **ADR Quality Platform**
   - Not just detection - comprehensive quality improvement
   - Benchmarking vs. national averages
   - MIPS quality metric submission

3. **Upper GI Suite**
   - Esophageal cancer detection (Barrett's, early SCC)
   - Gastric cancer detection (Asian market focus)
   - Duodenal lesion detection (AMP, carcinoid)

4. **Clinical Validation Focus**
   - Peer-reviewed research partnerships
   - Real-world outcome studies
   - Malpractice defense support

### Market Positioning

**Positioning Statement:**
"For quality-focused gastroenterologists who need to improve their Adenoma Detection Rate, EndoDetectAI is a vendor-agnostic AI platform that provides real-time polyp detection and comprehensive quality analytics, unlike hardware-locked solutions from scope manufacturers."

**Value Proposition:**
- Improve ADR by 10-30% (reimbursement + credentialing)
- Reduce malpractice risk (AI-assisted procedures)
- Works with existing equipment (no capital expenditure)
- Comprehensive GI suite (colonoscopy + upper GI)

---

## 11. Go-to-Market Strategy

### Phase 1: Pilot Launch (Months 1-6)

**Target:** 8 GI centers (3-5 endoscopists each)

**Tactics:**
- Partner with 1-2 academic GI centers (research credibility)
- Free pilot in exchange for data and case studies
- Present validation data at DDW

**Expected Outcomes:**
- 8 suites deployed
- Clinical validation data (50+ procedures)
- 3-5 case studies for marketing

### Phase 2: Early Adopter Expansion (Months 7-18)

**Target:** 40 GI centers

**Tactics:**
- Conference presence (DDW, ACG, ASGE)
- Peer-to-peer referrals (early adopter case studies)
- Quality metric webinars (ADR improvement focus)

**Expected Outcomes:**
- $120K MRR
- Brand recognition in GI community
- 2-3 society partnerships

### Phase 3: Market Expansion (Months 19-36)

**Target:** 120 GI centers + enterprise deals

**Tactics:**
- Hospital system contracts (multi-site deals)
- ASC chain partnerships
- International expansion (EU CE Mark, Japan PMDA)

**Expected Outcomes:**
- $360K MRR
- Market leader position
- Series A fundraising

### Sales Strategy

**Sales Motion:**
1. **Conference Lead Generation** - Demo booth, live detection competition
2. **Pilot Deployment** - 30-day free trial with full support
3. **Validation Measurement** - Pre/post ADR comparison
4. **Conversion** - Annual subscription based on validated results

**Sales Team Structure:**
- Founder-led sales (first 20 customers)
- Clinical sales specialists (former device reps)
- Customer success (GI nurse or tech background)

### Marketing Channels

1. **Conferences** (DDW, ACG, ASGE) - $50K annual budget
2. **GI Society Partnerships** - ACG, ASGE corporate supporters
3. **Peer-Reviewed Research** - GIE, Gastrointestinal Endoscopy journal
4. **Webinars** - ADR quality improvement series
5. **Case Studies** - "AI saved my career" stories

---

## 12. Financial Projections

### Revenue Model

| Year | Suites | ARPU | ARR |
|------|--------|------|-----|
| Year 1 | 8 | $36,000 | $288,000 |
| Year 2 | 40 | $36,000 | $1,440,000 |
| Year 3 | 120 | $36,000 | $4,320,000 |
| Year 4 | 300 | $36,000 | $10,800,000 |
| Year 5 | 600 | $36,000 | $21,600,000 |

### Unit Economics (Year 3)

| Metric | Value |
|--------|-------|
| ARR | $4.32M |
| COGS | $650K (15%) |
| Gross Profit | $3.67M (85%) |
| Sales & Marketing | $1.3M (30%) |
| R&D | $1.3M (30%) |
| G&A | $650K (15%) |
| EBITDA | $420K (10%) |

### Funding Requirements

| Stage | Amount | Use | Runway |
|-------|--------|-----|--------|
| Pre-Seed | $500K | MVP + pilot | 12 months |
| Seed | $3M | FDA clearance + commercial launch | 18 months |
| Series A | $10M | Market expansion + enterprise sales | 24 months |

---

## 13. Risk Factors

### Regulatory Risks

| Risk | Impact | Mitigation |
|------|--------|------------|
| FDA clearance required | HIGH | De Novo pathway, clinical trial planning |
| FDA label limitations | MEDIUM | Real-time vs. offline detection positioning |
| State medical board regulations | LOW | FDA clearance preempts most state rules |

### Technical Risks

| Risk | Impact | Mitigation |
|------|--------|------------|
| Real-time latency | HIGH | Edge deployment, model optimization |
| Hardware integration | HIGH | Vendor partnerships, standard video capture |
| False negative liability | HIGH | >90% sensitivity target, disclaimer language |
| False positive alert fatigue | MEDIUM | >80% specificity target, alert tuning |

### Commercial Risks

| Risk | Impact | Mitigation |
|------|--------|------------|
| Competition (Medtronic, Fujifilm) | HIGH | Vendor-agnostic differentiation |
| Small market size | MEDIUM | International expansion |
| Slow adoption | MEDIUM | Clinical validation, reimbursement tie |
| Price pressure | LOW | High switching costs, proven ROI |

### Legal Risks

| Risk | Impact | Mitigation |
|------|--------|------------|
| Malpractice liability | HIGH | Product liability insurance, FDA clearance |
| Medical necessity challenges | LOW | Quality metric improvement justification |
| Data privacy (HIPAA) | MEDIUM | BAA compliance, de-identification |

---

## 14. Competitive Moat

### 1. Regulatory Moat (Strength: 9/10)

- **FDA De Novo clearance** for real-time AI detection
- **2-3 year pathway** creates barrier to entry
- **Clinical trial data** required for clearance

### 2. Data Moat (Strength: 8/10)

- **Proprietary video dataset** (scarce, expensive to acquire)
- **Pathology-confirmed annotations** (gold standard)
- **Longitudinal outcome data** (interval cancer tracking)

### 3. Integration Moat (Strength: 9/10)

- **Hardware lock-in** (once installed, hard to remove)
- **Workflow integration** (physicians rely on alerts)
- **Data accumulation** (more procedures = better model)

### 4. Switching Costs (Strength: 10/10)

- **Clinical workflow** (physicians accustomed to system)
- **Quality metrics** (historical ADR data in platform)
- **Training costs** (staff trained on specific system)
- **Re-training required** for competing system

---

## 15. Team Requirements

### Founding Team

**CEO (Co-Founder)**
- Healthcare AI experience
- GI device background (Olympus, Fujifilm, Medtronic)
- Fundraising experience

**CTO (Co-Founder)**
- Computer vision / medical imaging background
- Real-time video processing expertise
- FDA software experience

**CMO (Co-Founder or Advisor)**
- Gastroenterologist MD
- Academic credibility (research publications)
- GI society relationships

### Key Hires (Year 1)

1. **ML Engineer** - CNN training, video processing
2. **Clinical Research Manager** - Data collection, validation studies
3. **Regulatory Affairs Specialist** - FDA submission preparation
4. **Clinical Sales Specialist** - Former GI device rep

### Advisory Board

1. **Academic Gastroenterologist** - Top GI research center
2. **GI Quality Expert** - ADR, quality metrics background
3. **FDA Regulatory Counsel** - Medical device AI experience
4. **Malpractice Attorney** - Liability risk assessment

---

## 16. Success Metrics

### Product Metrics

| Metric | Target (6 months) | Target (12 months) |
|--------|-------------------|--------------------|
| Sensitivity (polyps >5mm) | >90% | >95% |
| Specificity | >80% | >85% |
| Latency | <200ms | <100ms |
| Uptime | 99% | 99.9% |

### Commercial Metrics

| Metric | Target (6 months) | Target (12 months) |
|--------|-------------------|--------------------|
| Active Suites | 8 | 40 |
| MRR | $24K | $120K |
| ADR Improvement (avg) | 10% | 15% |
| Net Retention | 100% | 110% |
| NPS | 50 | 70 |

### Clinical Validation Metrics

| Metric | Target |
|--------|--------|
| Peer-reviewed publications | 1 (Year 1) |
| Conference presentations | 3 (Year 1) |
| Case study library | 10+ (Year 1) |
| FDA clearance submitted | Month 12 |

---

## 17. Critical Success Factors

### Must-Have for Success

1. **Clinical Validation** (CRITICAL)
   - >90% sensitivity cannot be compromised
   - Peer-reviewed publication required
   - ADR improvement must be proven

2. **Regulatory Clearance** (CRITICAL)
   - FDA De Novo pathway
   - Clinical trial design
   - Label limitations negotiated

3. **Physician Adoption** (CRITICAL)
   - Workflow integration seamless
   - Alert fatigue minimized
   - Training costs low

4. **Distribution Partnerships** (IMPORTANT)
   - GI device manufacturers (OEM deals)
   - GI societies (endorsements)
   - ASC chains (multi-site deals)

### Red Flags to Monitor

- Sensitivity <90% (cannot miss polyps)
- Latency >200ms (not real-time)
- FDA label too restrictive (limits utility)
- Slow adoption (physician resistance)
- Competitor price war (margin compression)

---

## 18. Exit Strategy

### Potential Acquirers

| Acquirer | Rationale | Probability |
|----------|-----------|-------------|
| Medtronic | GI Genius expansion | HIGH |
| Fujifilm | AI platform acquisition | HIGH |
| Olympus | EndoAid enhancement | MEDIUM |
| Boston Scientific | GI portfolio expansion | MEDIUM |
| Koninklijke Philips | Healthcare AI portfolio | LOW |
| Private Equity | Roll-up platform | MEDIUM |

### Exit Scenarios

**Acquisition (Most Likely)**
- Timeline: 5-7 years
- Valuation: $200-500M
- Trigger: 500+ suites, $20M+ ARR

**IPO (Less Likely)**
- Timeline: 8+ years
- Valuation: $500M-1B
- Trigger: Market leadership, 1000+ suites

### Preparing for Exit

- Build defensible IP portfolio (patents, data)
- Maintain clean cap table
- Document clinical validation rigorously
- Expand internationally (multiple markets)
- Diversify product suite (upper GI, therapeutics)

---

## 19. Next Steps (90 Days)

### Month 1: Foundation
- [ ] Incorporate entity
- [ ] Secure GI center partnership #1
- [ ] Hire ML Engineer
- [ ] Set up data infrastructure
- [ ] Begin data collection

### Month 2: Development
- [ ] Collect 50+ annotated polyp videos
- [ ] Train initial detection model
- [ ] Build real-time inference pipeline
- [ ] Deploy test system at partner site

### Month 3: Validation
- [ ] Run 30+ procedure validation
- [ ] Measure initial clinical performance
- [ ] Document first case study
- [ ] Begin regulatory pathway planning
- [ ] Start conversations with GI center #2

---

## 20. Appendices

### A. Adenoma Detection Rate (ADR) Explained

**Definition:** Percentage of screening colonoscopies where at least one adenomatous polyp is detected.

**Clinical Significance:**
- ADR is inversely correlated with interval cancer risk
- 1% increase in ADR = 3% decrease in interval cancer
- National benchmark: 25% (men), 15% (women)

**Quality Metric Status:**
- MIPS (Medicare) quality measure
- Publicly reported on Physician Compare
- Hospital credentialing criterion

**Reimbursement Impact:**
- Low ADR = MIPS penalty (-9% reimbursement)
- High ADR = MIPS bonus (+9% reimbursement)
- ~$20K annual impact per physician

### B. Colonoscopy Statistics

- **19M+ procedures annually** in US
- **4% annual growth** (screening age lowered to 45)
- **Average payment:** $500-1,500 per procedure
- **Ambulatory setting:** 70% of procedures
- **Screening vs. surveillance:** 60% screening, 40% surveillance

### C. Competitive Product Analysis

**Medtronic GI Genius:**
- FDA approved 2021
- $10,000/year subscription
- Olympus scopes only
- 13% ADR improvement in clinical trial

**Fujifilm CAD EYE:**
- CE Mark (Europe), FDA pending (US)
- Integrated with ELUXEO scopes
- Pricing undisclosed (likely scope-embedded)

**Iterative Scans SKOUT:**
- FDA approved 2023
- Colonoscopy only (no upper GI)
- Subscription pricing undisclosed

### D. Clinical References

1. **Repici et al. (2022)** - GI Genius randomized trial: 13% ADR improvement
2. **Wang et al. (2020)** - Deep learning polyp detection: 94% sensitivity
3. **East et al. (2023)** - AI-assisted colonoscopy meta-analysis: 10% ADR improvement
4. **MIPS ADR Measure** - CMS Quality Measure ID: 299

---

## Conclusion

EndoDetectAI represents a compelling opportunity to address a critical clinical problem (missed polyps) while aligning with economic incentives (ADR-based reimbursement). The combination of:

1. **Strong clinical validation** (proven ADR improvement)
2. **Regulatory moat** (FDA clearance required)
3. **High switching costs** (workflow integration)
4. **Clear ROI** (reimbursement + liability reduction)

Creates a defensible business with strong unit economics and exit potential.

**Key Risk:** FDA clearance timeline and scope of label

**Key Success Factor:** >90% sensitivity without compromising real-time latency

**Recommendation:** PURSUE with focus on clinical validation and regulatory strategy.

---

**Venture Score: 8.00/10**

**Status:** GO
**Priority:** HIGH (top 5 of current pipeline)

**Next Action:** Schedule meeting with gastroenterologist advisor to validate clinical assumptions and secure pilot site partnership.
